13F Holdings
中文EN

LIMN Liminatus Pharma, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1971387 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,098.0%
TTM EPS YoY-860.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-471.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets91.2%
Debt / equity0.00x
Current ratio1.12x
Interest coverage-53.78x

Cash quality & payout

Operating cash flow / net income0.32x
Accruals ratio-321.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense—$2.69M
SG&A expense$2.97M$644,619
Operating income-$2.97M-$3.33M
Interest expense$215,903$338,882
Net income-$10.21M-$3.55M
EBITDA-$2.97M—
EPS (basic)-0.43-0.20
EPS (diluted)-0.43-0.20
Weighted avg. shares (diluted)23.75M17.50M
Balance sheet
Cash & equivalents$337,655$56,319
Current assets$500,574$5.28M
PP&E, net$12,221$941
Total assets$512,795$5.41M
Current liabilities$10.30M$24.75M
Short-term debt$1.44M$19.97M
Total liabilities$10.33M$24.75M
Shareholders' equity-$9.81M-$19.34M
Shares outstanding27.06M17.50M
Cash flow statement
Operating cash flow-$9.96M-$1.45M
Capital expenditure$13,108—
Free cash flow-$9.98M—
Investing cash flow-$788,108-$2.85M
Financing cash flow$11.03M$3.92M
Depreciation & amortization$1,828—

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.